Page 129 - Haematologica Vol. 109 - July 2024

ARTICLE - Cytotoxic reprogramming for BiTE immunotherapy M. Casey et al.
immunotherapy. Nat Rev Immunol. 2022;22(2):85-96.
16. Li J, Piskol R, Ybarra R, et al. CD3 bispecific antibody-induced
cytokine release is dispensable for cytotoxic T cell activity. Sci
Transl Med. 2019;11(508):eaax8861.
17. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition
reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697-709.
18. Bailey SR, Vatsa S, Larson RC, et al. Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov. 2022;3(2):136-153.
19. Manni S, Del Bufalo F, Merli P, et al. Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun. 2023;14(1):3423.
20. Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15(6):388-400.
21. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.
22. Ishii K, Pouzolles M, Chien CD, et al. Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. J Clin Invest. 2020;130(10):5425-5443.
23. Larson RC, Kann MC, Bailey SR, et al. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours. Nature. 2022;604(7906):563-570.
24. Casey M, Lee C, Kwok W, et al. Regulatory T cells hamper the efficacy of T cell-engaging bispecific antibody therapy. Haematologica. 2024;109(3):787-789.
25. Casey M, Segawa K, Law SC, et al. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Leukemia. 2023;37(2):379-387.
26. Nakamura K, Kassem S, Cleynen A, et al. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell. 2018;33(4):634-648.
27. Lewis KE, Selby MJ, Masters G, et al. Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models. Oncoimmunology. 2017;7(1):e1377873.
28. Mittal D, Caramia F, Michiels S, et al. Improved treatment of breast cancer with anti-HER2 therapy requires interleukin-21 signaling in CD8+ T cells. Cancer Res. 2016;76(2):264-274.
29. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22(3):333-340.
30. Weulersse M, Asrir A, Pichler AC, et al. Eomes-dependent loss of the co-activating receptor CD226 restrains CD8(+) T cell anti- tumor functions and limits the efficacy of cancer immunotherapy. Immunity. 2020;53(4):824-839.
31. Braun M, Aguilera AR, Sundarrajan A, et al. CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8(+) T cells. Immunity. 2020;53(4):805-823.
32. Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4(1):61-71.
33. Tybulewicz VL, Henderson RB. Rho family GTPases and their regulators in lymphocytes. Nat Rev Immunol. 2009;9(9):630-644.
34. Dieckmann NM, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. The cytotoxic T lymphocyte immune synapse at a glance. J Cell Sci. 2016;129(15):2881-2886.
35. Zelle-Rieser C, Thangavadivel S, Biedermann R, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9(1):116.
36. Bailur JK, McCachren SS, Doxie DB, et al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. 2019;5(11):e127807.
37. Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346-351.
38. Wilkens AB, Fulton EC, Pont MJ, et al. NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness. Blood. 2022;140(21):2261-2275.
39. Rainone M, Ngo D, Baird JH, et al. Interferon-γ blockade in CAR T-cell therapy-associated macrophage activation syndrome/ hemophagocytic lymphohistiocytosis. Blood Adv. 2023;7(4):533-536.
40. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn’s disease. Gastroenterology. 2005;128(3):687-694.
41. Suto A, Wurster AL, Reiner SL, Grusby MJ. IL-21 inhibits IFN- gamma production in developing Th1 cells through the repression of Eomesodermin expression. J Immunol. 2006;177(6):3721-3727.
42. Tian Y, Zajac AJ. IL-21 and T cell differentiation: consider the context. Trends Immunol. 2016;37(8):557-568.
43. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov. 2014;13(5):379-395.
44. White L, Krishnan S, Strbo N, et al. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood. 2007;109(9):3873-3880.
45. Browning RL, Byrd WH, Gupta N, et al. Lenalidomide induces interleukin-21 production by T cells and enhances IL21-mediated cytotoxicity in chronic lymphocytic leukemia B cells. Cancer Immunol Res. 2016;4(8):698-707.
46. Meermeier EW, Welsh SJ, Sharik ME, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021;2(4):354-369.
47. Li Y, Cong Y, Jia M, et al. Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nat Commun. 2021;12(1):951.
48. Timmerman JM, Byrd JC, Andorsky DJ, et al. A phase I dose- finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res. 2012;18(20):5752-5760.
49. Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood. 2002;99(10):3756-3762.
50. Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 2010;115(3):570-580.
51. Gowda A, Roda J, Hussain SR, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 2008;111(9):4723-4730.
Haematologica | 109 July 2024
2143